Nina Buchtele and Bernhard Nagler, together with their co-authors, were presented with the "Garner King Award - Best Clinical or Quality Improvement Study" at the Critical Care Canada Forum in Toronto for a study on extracorporeal membrane oxygenation.
Nina Buchtele and Bernhard Nagler (both Department of Medicine I, Intensive Care Unit 13i2) received the award together with their co-authors (T. Staudinger, P. Schellongowski, L. Traby (both Department of Medicine I), M. Schwameis, E. Lobmeyr-Länge (both Department of Emergency Medicine)) for the paper "Safety and Feasibility of Argatroban as Anticoagulant in Patients with Extracorporeal Membrane Oxygenation (ECMO) - A Prospective Randomized-controlled Pilot Trial".
The study, conducted at the Medical University of Vienna’s Internal Medicine Intensive Care Unit 13i2, shows that the modern blood thinner Argatroban is a safe and effective alternative to heparin in the treatment of critically ill patients with extracorporeal membrane oxygenation (ECMO). ECMO is used for life-threatening conditions such as severe respiratory or circulatory failure, where reliable and personalized anticoagulation is critical to prevent complications such as bleeding or clots.
The Critical Care Canada Forum in Toronto is a leading international conference that brings together experts in critical care medicine to present innovative research, best clinical practices and pioneering approaches to patient care. The Garner King Award, named after a pioneer in Canadian critical care medicine, recognizes both innovative research and exceptional clinical achievement. Each year, the award is presented to an individual or team that stands out for scientific excellence and significant advances in patient care.
